CHAPEL HILL, N.C., March 9, 2015 -- CROS NT today announced that it is extending its partnership with DATATRAKas part of its life science technology portfolio. The partnership allows CROS NT to provide DATATRAK's Unified eClinical® platform which includes Electronic Data Capture (EDC), Clinical Trial Management System (CTMS), randomization and clinical trial supply management (RTSM) as well as a web-based patient diary (ePRO).

CROS NT joined DATATRAK CONNECT® Partner program in order to offer a unified, cloud-based technology solution to enhance the quality of clinical data in an efficient and convenient manner for both drug and device development companies. Since joining the program, CROS NT has implemented DATATRAK's eClinical platform in a large number of studies across U.S. and Europe.

At the beginning of the year, DATATRAK announced a new release of its DATATRAK ONE® unified platform with three applications now available to support individual or cross-study functionality:

  • The Cross Study Manager enables real time data, analytics and reporting at the trial or cross-study level for over 100 fields
  • The Scheduler delivers information to the appropriate person in an individual trial or across a program of studies
  • File Versioning improves data quality with a unified view of files online in real-time

Paul Fardy, Chief Operations Officer for CROS NT, said, "Our decision to extend our participation in the DATATRAK Partner Program is a reflection of the success we've had in the past implementing the unified platform in some of our global studies as well asDATATRAK's commitment to constantly improving the system's functionality to meet the increasing demands of Sponsors for real-time data analysis and reporting capabilities."

Laurence P. Birch, Chairman and CEO for DATATRAK, said. "We are proud to partner with CROS NT to bring the benefits of our unified platform to trials around the globe.  Our mutual success is driven by delivering a simplified eClinical platform that removes time consuming and costly complexity, including data integration and long wait times for cross-study reporting. We look forward to expanding our partnership with CROS NT in 2015 and beyond."

Join DATATRAK Thought Leaders:

Tweet:  Global CRO @CROSNT extends partnership with @DATATRAKinc recognizing commitment to removing #clinicaltrial complexity

CROS NT is an international Contract Research Organization (CRO) specialized in clinical data services including Biostatistics methodology, programming and analysis, Clinical Data Management, Medical Writing and Clinical Technologies (EDC, ePRO, IWRS, CTMS). Founded in 1992, CROS NT is well-established in delivering quality, timely and cost-effective services for pharmaceutical, biotechnology and medical device companies as well as academic institutions, associations and other CROs. The company has provided expert services for over 1,000 pre- and post-market studies in a very wide range of therapeutic areas and indications.

About DATATRAK International, Inc.
DATATRAK International is a worldwide technology and services company delivering Unified eClinical® solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Preclinical and Phase I - Phase IV drug and device studies as well as device studies in multiple languages throughout the world. DATATRAK is located in Cleveland, Ohio; Bryan, Texas; Cary (RTP), North Carolina, Chicago, Illinois; and London, England.  For more information, visit

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on November 13, 2014 announcing its results for the third quarter 2014. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.